Phase II Study: Taphalgin Shows Promising Results for Patients with Cancer Pain Syndromes

09.12.2020

Today, we mark another significant milestone in clinical research with the successful conclusion of a Phase II study for Taphalgin, which ended on December 8, 2020. This open-label, multicenter, randomized trial centered on evaluating the efficacy, safety, and pharmacokinetics of Taphalgin in addressing cancer pain syndromes. The positive outcomes further solidify Taphalgin's potential as an effective solution for patients grappling with cancer-related pain.

Phase II Study: Taphalgin Shows Promising Results for Patients with Cancer Pain Syndromes

About

Recent news

Taphalgin Completes Another Successful Phase III Clinical Study for Postoperative Pain

Phase III Study Validates Taphalgin‘s Efficacy for Cancer Pain Management

Сontacts

©2016-2023 PVP LABS PTE. LTD